Inhibikase Therapeutics, Inc.
IKT
$2.40
$0.03861.64%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -100.00% | 990.41% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -100.00% | 990.41% |
| Cost of Revenue | 29.90% | -32.19% | -3.60% | -1.68% | 8.18% |
| Gross Profit | -33.18% | 30.40% | 1.37% | -0.41% | -5.77% |
| SG&A Expenses | 0.91% | 10.75% | 5.49% | 4.18% | 5.47% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 20.19% | -20.07% | 0.06% | 0.12% | 7.26% |
| Operating Income | -22.20% | 18.57% | -1.43% | -1.58% | -5.67% |
| Income Before Tax | -25.74% | 14.16% | -3.84% | 2.36% | -2.24% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -25.74% | 14.16% | -3.84% | 2.36% | -2.24% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -25.74% | 14.16% | -3.84% | 2.36% | -2.24% |
| EBIT | -22.20% | 18.57% | -1.43% | -1.58% | -5.67% |
| EBITDA | -22.23% | 16.53% | -1.40% | -1.55% | -5.54% |
| EPS Basic | 12.77% | 29.80% | 24.91% | 32.96% | 29.92% |
| Normalized Basic EPS | 12.75% | 29.81% | 24.92% | 32.97% | 29.92% |
| EPS Diluted | 12.77% | 29.80% | 24.91% | 32.96% | 29.92% |
| Normalized Diluted EPS | 12.75% | 29.81% | 24.92% | 32.97% | 29.92% |
| Average Basic Shares Outstanding | 44.13% | 22.29% | 38.29% | 45.65% | 45.89% |
| Average Diluted Shares Outstanding | 44.13% | 22.29% | 38.29% | 45.65% | 45.89% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
